Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 901–1,000 of 1,003

The safety of ramucirumab for the treatment of colorectal cancer
Noguerido, A., Mulet-Margalef, N., Matos, I. G., Ros, J., Argilés, G., Élez, E., & Tabernero, J. M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1506762 · Cited by 20
Self-citation
Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases
Saad, A. M., & Abdel-Rahman, O. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1642324 · Cited by 20
Consensus Molecular Subtypes (CMS) Classification: a progress towards Subtype-Driven treatments in colorectal cancer
Kantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 19
BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer
Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
Ottaiano, A., Capozzi, M., Tafuto, S., Stefano, A. D., Divitiis, C. D., Romano, C., Avallone, A., & Nasti, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00766 · Cited by 20
Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
Kamiimabeppu, D., Osumi, H., Shinozaki, E., Ooki, A., Wakatsuki, T., Yoshino, K., Sato, T., Nakayama, I., Ogura, M., Takahari, D., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.13044 · Cited by 19
Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
Takeda, Y., Mise, Y., Takahashi, Y., Ito, H., Inoue, Y., Yoshioka, R., Ono, Y., & Saiura, A. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11015-9 · Cited by 19
Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients
Walter, F., Rottler, M., Nierer, L., Landry, G., Well, J., Rogowski, P., Mohnike, K., Seidensticker, M., Ricke, J., Belka, C., et al. (2021) · Cancers · doi:10.3390/cancers13246250 · Cited by 19
Self-citation
Comprehensive Imaging Characterization of Colorectal Liver Metastases
Maclean, D., Tsakok, M., Gleeson, F. V., Breen, D. J., Goldin, R. D., Primrose, J. M., Harris, A. L., & Franklin, J. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.730854 · Cited by 23
Single-session transarterial chemoembolization combined with percutaneous thermal ablation in liver metastases 3 cm or larger
Kobe, A. R., Tselikas, L., Deschamps, F., Roux, C., Delpla, A., Varin, E., Hakimé, A., & de Baère, T. (2022) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2022.05.008 · Cited by 19
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19
High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients
Mauro, A. D., Santorsola, M., Savarese, G., Sirica, R., Ianniello, M., Cossu, A. M., Ceccarelli, A., Sabbatino, F., Bocchetti, M., Carratù, A. C., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05927-9 · Cited by 19
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
Cremolini, C., Pietrantonio, F., Tomasello, G., Dadduzio, V., Moretto, R., Morano, F., Schirripa, M., Antoniotti, C., Fucà, G., Bergamo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000241 · Cited by 19
Self-citation
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma
Peeters, M., Forget, F., Karthaus, M., Valladares‐Ayerbes, M., Zaniboni, A., Demonty, G., Guan, X., & Rivera, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000297 · Cited by 19
Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer
Liu, J., Lu, C., Zhang, F., Lv, W., & Liu, C. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.07.026 · Cited by 19
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study
Dote, S., Itakura, S., Kamei, K., Hira, D., Noda, S., Kobayashi, Y., & Terada, T. (2018) · BMC Cancer · doi:10.1186/s12885-018-4862-z · Cited by 19
Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review
Sclafani, F., Hesselberg, G., Thompson, S. R., Truskett, P. G., Haghighi, K. S., Rao, S., & Goldstein, D. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25320 · Cited by 19
68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
Janice, S. H. T., Charles, X., Yen, S. K., Youquan, L., Tuan, J. K. L., Chua, E. T., Terence, W. K. T., Michael, L. C. W., Lui, S. L., Tay, K. J., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0288 · Cited by 19
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial
Riechelmann, R. P., Leite, L. A. S., Bariani, G. M., Glasberg, J., Rivelli, T. G., da Fonseca, L. G., Nebuloni, D. R., Braghiroli, M. I., Queiroz, M. A., Isejima, A. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0067 · Cited by 19
Self-citation
Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM)
Larentzakis, A. V., O’Dwyer, S., Becker, J., Shuweihdi, F., Aziz, O., Selvasekar, C. R., Fulford, P. E., Renehan, A. G., & Wilson, M. S. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.07.008 · Cited by 19
DNA Repair Capacity and Response to Treatment of Colon Cancer
Vodicka, P., Vodenkova, S., Buchler, T., & Vodickova, L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0070 · Cited by 19
Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
Varghese, A. M., Cardin, D. B., Hersch, J., Benson, A. B., Höchster, H. S., Makris, L., Hamada, K., Berlin, J. D., & Saltz, L. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2743 · Cited by 20
Self-citation
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Alfonso, P. G., García‐Carbonero, R., García‐Foncillas, J., Pérez‐Segura, P., Salazar, R., Vera, R., y Cajal, S. R., Hernández‐Losa, J., Landolfi, S., Musulén, E., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02357-z · Cited by 18
Self-citation
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Sobrero, A. F., Lenz, H., Eng, C., Scheithauer, W., Middleton, G., Chen, W., Esser, R., Nippgen, J., & Burris, H. A. (2020) · The Oncologist · doi:10.1002/onco.13591 · Cited by 19
Self-citation
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience
Jolivet, C., Nassabein, R. M., Soulières, D., Weng, X., Amireault, C., Ayoub, J.-P., Beauregard, P., Blais, N., Carrier, C., Cloutier, A., et al. (2020) · The Oncologist · doi:10.1002/onco.13626 · Cited by 19
Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with RAS ‐mutated or BRAF ‐mutated metastatic colorectal cancer
Hamfjord, J., Guren, T. K., Glimelius, B. L. G., Sørbye, H., Pfeiffer, P., Dajani, O. F., Lingjærde, O. C., Tveit, K. M., Pallisgaard, N., Spindler, K. G., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33672 · Cited by 19
Self-citation
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies
Moretto, R., Rossini, D., Conca, V., Lonardi, S., Rasola, C., Antoniotti, C., Santini, D., Marmorino, F., Tomasello, G., Borelli, B., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01483-x · Cited by 20
Self-citation
Colon cancer exosome-associated HSP90B1 initiates pre-metastatic niche formation in the liver by polarizing M1 macrophage into M2 phenotype
Li, S., Fu, X., Ning, D., Liu, Q., Zhao, J., Cheng, Q., Chen, X., & Jiang, L. (2025) · Biology Direct · doi:10.1186/s13062-025-00623-0 · Cited by 20
The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis
Gelsomino, F., Gardini, A. C., Rossini, D., Boccaccino, A., Masi, G., Cremolini, C., Spallanzani, A., Viola, M. G., Garajová, I., Salati, M., et al. (2020) · Cancers · doi:10.3390/cancers12041022 · Cited by 18
Self-citation
Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy
O'Cathail, S. M., Smith, T., Owens, R., Zeniou, A., Tsang, Y. M., Holyoake, D., Murray, L. J., Harrison, M., & Hawkins, M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.08.012 · Cited by 18
Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing
Liang, Y., Tsai, J., Cheng, Y., Chan, K.-Y., Hsu, W.-L., Lee, C.-C., Chen, K., & Yeh, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-88648-z · Cited by 17
The impact of timely cancer diagnosis on age disparities in colon cancer survival
Pilleron, S., Maringe, C., Charvat, H., Atkinson, J., Morris, E. J. A., & Sarfati, D. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.04.003 · Cited by 18
Borderline resectable for colorectal liver metastases: Present status and future perspective
Kitano, Y., Hayashi, H., Matsumoto, T., Kinoshita, S., Sato, H., Shiraishi, Y., Nakao, Y., Kaida, T., Imai, K., Yamashita, Y., et al. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i8.756 · Cited by 18
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion
Cantero-Recasens, G., Alonso‐Marañón, J., Lobo‐Jarne, T., Garrido, M., Iglesias, M., Espinosa, L., & Malhotra, V. (2022) · eLife · doi:10.7554/elife.73926 · Cited by 18
Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness
Xu, Y.-J., Zhang, P., Hu, J., Liang, H., Zhu, Y., Cui, Y., Niu, P., Xu, M., & Liu, M. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i4.920 · Cited by 18
Clinical Significance of Early Carcinoembryonic Antigen Change in Patients With Nonmetastatic Colorectal Cancer
Jo, Y., Lee, J., Cho, E., Lee, H. S., Shin, S., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.739614 · Cited by 18
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
Kuboki, Y., Terazawa, T., Masuishi, T., Nakamura, M., Watanabe, J., Ojima, H., Makiyama, A., Kotaka, M., Hara, H., Kagawa, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02212-2 · Cited by 19
Self-citation
The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives
Carconi, C., Cerreti, M., Roberto, M., Arrivi, G., D’Ambrosio, G., Felice, F. D., Civita, M. A. D., Iafrate, F., Lucatelli, P., Magliocca, F. M., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103990 · Cited by 19
Signet Ring Cell Colorectal and Appendiceal Cancer: A Small Signet Ring Cell Component Is Also Associated with Poor Outcome
Enblad, M., Egerszegi, P. P., Birgisson, H., Sjöblom, T., Glimelius, B. L. G., & Folkesson, J. (2023) · Cancers · doi:10.3390/cancers15092497 · Cited by 18
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score
Ziranu, P., Ferrari, P. A., Guerrera, F., Bertoglio, P., Tamburrini, A., Pretta, A., Lybéris, P., Grimaldi, G., Lai, E., Santoru, M., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107342 · Cited by 19
Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation
Zeeuw, M. J., Wesdorp, N. J., Ali, M., Bakker, A.-J. J. J., Voigt, K. R., Starmans, M. P. A., Roor, J., Kemna, R., van Waesberghe, J. H. T. M., van den Bergh, J. E., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114185 · Cited by 18
Self-citation
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases
Pietrantonio, F., Bartolomeo, M. D., Cotsoglou, C., Mennitto, A., Berenato, R., Morano, F., Coppa, J. C., Perrone, F., Iacovelli, R., Milione, M., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.09.007 · Cited by 18
Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
Gouverneur, A., Claraz, P., Rousset, M., Arnaud, M., Fourrier‐Réglat, A., Pariente, A., Aparicio, T., Miremont‐Salamé, G., & Noïze, P. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0529-y · Cited by 18
Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)
Decoster, L., Kenis, C., Naessens, B., Houbier, G., Man, M. D., Lambrecht, G. L. Y., Monsaert, E., Moons, V., Vergauwe, P. L., Prenen, H., et al. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.10.002 · Cited by 18
Role of circulating tumor DNA in the management of patients with colorectal cancer
Moati, É., Taly, V., Didelot, A., Perkins, G., Blons, H., Taı̈eb, J., Laurent‐Puig, P., & Zaanan, A. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.03.002 · Cited by 19
Self-citation
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
Unseld, M., Drimmel, M., Siebenhüner, A. R., Gleiß, A., Bianconi, D., Kieler, M., Scheithauer, W., Winder, T., & Prager, G. W. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.012 · Cited by 18
Self-citation
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
Nakayama, G., Mitsuma, A., Sunagawa, Y., Ishigure, K., Yokoyama, H., Matsui, T., Nakayama, H., Nakata, K., Ishiyama, A., Asada, T., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0640 · Cited by 18
Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
Hirokawa, F., Asakuma, M., Komeda, K., Shimizu, T., Inoue, Y. H., Kagota, S., Tomioka, A., & Uchiyama, K. (2018) · Surgery Today · doi:10.1007/s00595-018-1716-x · Cited by 18
Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma
Franczak, C., Dubouis, L., Gilson, P., Husson, M., Rouyer, M., Demange, J., Leroux, A., Merlin, J., & Harlé, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212801 · Cited by 18
Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour DNA Mutations
Galbiati, S., Damin, F., Ferraro, L., Soriani, N., Burgio, V., Ronzoni, M., Gianni, L., Ferrari, M., & Chiari, M. (2019) · Cells · doi:10.3390/cells8080769 · Cited by 17
Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma
Sebastian, N., Tan, Y., Miller, E. D., Williams, T. M., Noonan, A. M., Hays, J. L., Abdel‐Misih, S., & Diaz, D. A. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11154 · Cited by 18
FDG PET/TC en el cáncer colorrectal
Rodríguez‐Fraile, M., Cozar, M., Sabaté-Llobera, A., Caresia-Aróztegui, A. P., Bolton, R. C. D., Orcajo-Rincón, J., de Arcocha-Torres, M., García‐Velloso, M. J., & García-Talavera, P. (2019) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2019.09.009 · Cited by 18
Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy
Araújo, R. L. C., Milani, J. M., Armentano, D. P., Moreira, R. B., Pinto, G. S. F., de Castro, L. A., & Lucchesi, F. R. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25784 · Cited by 18
Antitumour immunity invoked by hepatic arterial infusion of first‐line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8–12 years of follow‐up
Abrahamsson, H., Jensen, B. V., Berven, L. L., Nielsen, D. L., Benth, J. Š., Johansen, J. S., Larsen, F. O., Johansen, J. S., & Ree, A. H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32847 · Cited by 18
Comparison of sequential, delayed and simultaneous resection strategies for synchronous colorectal liver metastases
Wang, L., Wang, H., Jin, K., Li, J., & Xing, B.-C. (2020) · BMC Surgery · doi:10.1186/s12893-020-0681-7 · Cited by 18
Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants
Raber, I., Frazer, M. B., Zerillo, J. A., & Asnani, A. H. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.04.005 · Cited by 18
The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
Djanani, A. M., Eller, S., Öfner, D., Troppmair, J., & Maglione, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239001 · Cited by 18
Prognostic value of metabolic parameters on 18F-fluorodeoxyglucose positron tomography/computed tomography in classical rectal adenocarcinoma
Choi, B. W., Kang, S., Bae, S. U., Jeong, W. K., Baek, S. K., Song, B., Won, K. S., & Kim, H. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-92118-x · Cited by 18
The Impact of Primary Tumor Resection on Survival in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases
Doah, K. Y., Shin, U. S., Jeon, B. H., Cho, S. S., & Moon, S. M. (2021) · Annals of Coloproctology · doi:10.3393/ac.2020.09.15.1 · Cited by 18
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
Lai, E., Cascinu, S., & Scartozzi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637823 · Cited by 19
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
Damato, A., Bergamo, F., Antonuzzo, L., Nasti, G., Iachetta, F., Romagnani, A., Gervasi, E., Larocca, M., & Pinto, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766500 · Cited by 20
Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence
Viganò, L., Arachchige, V. S. J., & Fiz, F. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i6.608 · Cited by 20
A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial
Iwamoto, S., Ooki, A., Morita, S., Hara, H., Tanioka, H., Satake, H., Kataoka, M., Kotaka, M., Kagawa, Y., Nakamura, M., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1623 · Cited by 17
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
Chen, Y., Wu, J., Cheng, K., Li, Z., Luo, D., Qiu, M., Gou, H., Yi, C., Li, Q., Wang, X., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0901 · Cited by 17
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
Bahl, A., Talwar, V., Sirohi, B., Mehta, P., Arya, D., Shrivastava, G., Dahiya, A., & Pavithran, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00964 · Cited by 18
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Fernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad117 · Cited by 17
Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience.
Sparchez, Z. A., Mocan, T., Hajjar, N. A., Bartoş, A., Hagiu, C., Matei, D. M., Crăciun, R., Mocan, L. P., Spârchez, M., & Leucuta, D. (2019) · Medical Ultrasonography · doi:10.11152/mu-1957 · Cited by 17
Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study
Helmberger, T. K., Arnold, D., Bilbao, J. I., de Jong, N., Maleux, G. A., Nordlund, A., Peynırcıoğlu, B., Sangro, B., Sharma, R. A., & Walk, A. (2020) · JMIR Research Protocols · doi:10.2196/16296 · Cited by 17
Self-citation
An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis
Zhao, Y., Chen, C., Xu, X., Ge, X., Ding, K., Zheng, S. S., Wang, J., & Sun, L. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1901464 · Cited by 17
Evolutions of the Management of Colorectal Cancer Liver Metastasis: A Bibliometric Analysis
Jin, B., Wu, X., Xu, G., Xing, J., Wang, Y., Yang, H., Du, S., & Mao, Y. (2021) · Journal of Cancer · doi:10.7150/jca.52842 · Cited by 17
Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer
Jiménez‐Luna, C., González‐Flores, E., Ortíz, R., Martínez-González, L. J., Antúnez-Rodríguez, A., Ruíz, M. E., Melguizo, C., Caba, O., & Prados, J. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112248 · Cited by 17
Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis
Kvietkauskas, M., Žitkutė, V., Leber, B., Strupas, K., Stiegler, P., & Schemmer, P. (2021) · Nutrients · doi:10.3390/nu13062035 · Cited by 17
Long-term outcomes of ultrasound-guided percutaneous microwave ablation versus resection for colorectal cancer liver metastases: a propensity-score matched study
Huang, Z., Pan, Y., Zhou, P., Li, S., & Li, K. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1968511 · Cited by 17
Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy
Peng, J., Liu, Y., Li, W., Lin, Y., Sun, H., Pan, Z., Wu, X., Fan, W., & Lin, J. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211066206 · Cited by 18
External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort
Bolhuis, K., Wensink, G. E., Elferink, M. A. G., Bond, M. J. G., Dijksterhuis, W. P. M., Fijneman, R. J. A., Kranenburg, O., Rinkes, I. H. M. B., Koopman, M., Swijnenburg, R., et al. (2022) · Cancers · doi:10.3390/cancers14102356 · Cited by 17
Self-citation
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study
Uutela, A., Österlund, E., Halonen, P., Kallio, R. S., Ålgars, A., Salminen, T., Lamminmäki, A., Soveri, L., Ristamäki, R., Lehtomäki, K., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01858-8 · Cited by 18
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
Yoshino, T., Cutsem, E. V., Li, J., Shen, L., Kim, T. W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100511 · Cited by 18
Self-citation
Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases
Wong, G. Y. M., Diakos, C. I., Hugh, T. J., & Molloy, M. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116091 · Cited by 19
Characterization of KRAS Mutational Regression in Oligometastatic Patients
Ottaiano, A., d’Aragona, R. P. D. V., Trotta, A. M., Santorsola, M., Napolitano, M., Scognamiglio, G., Tatangelo, F., Grieco, P., Zappavigna, S., Granata, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898561 · Cited by 17
Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi‐institutional retrospective study
Noda, T., Takahashi, H., Tei, M., Nishida, N., Hata, T., Takeda, Y., Ohue, M., Wada, H., Mizushima, T., Asaoka, T., et al. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12631 · Cited by 17
Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis
Lin, L., Zeng, X., Liang, S., Wang, Y., Dai, X., Sun, Y., & Wu, Z. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-965 · Cited by 16
Predictive Factors for Local Recurrence after Intraoperative Microwave Ablation for Colorectal Liver Metastases
Wada, Y., Takami, Y., Ryu, T., Uchino, Y., Kugiyama, T., Nomura, Y., & Saitsu, H. (2022) · Cancers · doi:10.3390/cancers15010122 · Cited by 17
Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy
Yang, Y., Meng, W., & Wang, Z. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2804069 · Cited by 17
Hungatella hathewayi impairs the sensitivity of colorectal cancer cells to 5-FU through decreasing CDX2 expression
Huang, Z. L., Wang, C., Huang, Q., Yan, Z., & Yin, Z. (2023) · Human Cell · doi:10.1007/s13577-023-00938-y · Cited by 19
Study Protocol STEREOLAB: Stereotactic Liver Ablation Assisted with Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment
Paolucci, I., Silva, J. A. M., Lin, Y., Fellman, B. M., Jones, A. K., Tatsui, C. E., Weinberg, J. S., Ruiz, J. R., Tan, J., Brock, K. K., et al. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-023-03524-9 · Cited by 17
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
Flecchia, C., Auclin, É., Alouani, E. L., Mercier, M., Hollebecque, A., Turpin, A., Mazard, T., Pernot, S., Dutherage, M., Cohen, R., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02524-3 · Cited by 18
Self-citation
The Added Value of Transcatheter CT Hepatic Angiography (CTHA) Image Guidance in Percutaneous Thermal Liver Ablation: An Experts’ Opinion Pictorial Essay
Puijk, R. S., Dijkstra, M., van der Lei, S., Schulz, H. H., Vos, D. J. W., Timmer, F. E. F., Geboers, B., Scheffer, H. J., de Vries, J. J. J., Smits, M. L. J., et al. (2024) · Cancers · doi:10.3390/cancers16061193 · Cited by 17
Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy
Hong, Y., Li, J., Xu, N., Shu, W., Chen, F., Mi, Y., Geng, H., & Li, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604154 · Cited by 17
Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
Lin, C., Lin, T., Chen, C., Chen, M.-C., & Chen, C.-P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190497 · Cited by 17
Technical Validation of a Reverse-Transcription Quantitative Polymerase Chain Reaction In Vitro Diagnostic Test for the Determination of MiR-31-3p Expression Levels in Formalin-Fixed Paraffin-Embedded Metastatic Colorectal Cancer Tumor Specimens
Ramon, L., David, C., Fontaine, K., Lallet, E., Marcaillou, C., Martin‐Lannerée, S., Decaulne, V., Vazart, C., Gélibert, A.-H., Abdelali, R. B., et al. (2018) · Biomarker Insights · doi:10.1177/1177271918763357 · Cited by 17
Morbidity and Mortality Rates from Digestive Diseases in the RF Northwestern Federal District (NWFD) and Measures to Reduce Them
Baranovsky, A. Y., Belyaev, А. М., & Александровна, К. Э. (2019) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2019-29-1-36-46 · Cited by 17
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
Ongaro, E., Cremolini, C., Rossini, D., Corti, F., Pagani, F., Morelli, L., Urbani, L., Masi, G., Sposito, C., Filippi, B., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000496 · Cited by 17
Self-citation
Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience
Vernaleone, M., Bonomo, P., Cataldo, V. D., Saieva, C., Masi, L., Desideri, I., Greto, D., Francolini, G., Becherini, C., & Livi, L. (2019) · La radiologia medica · doi:10.1007/s11547-019-01042-8 · Cited by 17
Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers
Gherman, A., Bălăcescu, L., Cetean, S., Vlad, C. I., Bălăcescu, O., Irimie, A., & Lisencu, C. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062089 · Cited by 17
Small Nucleolar RNA, C/D Box 16 (SNORD16) Acts as a Potential Prognostic Biomarker in Colon Cancer
He, J., Liu, X., Qi, Z., Wang, Q., Lü, W., Zhang, Q., He, S., & Wang, Z. (2020) · Dose-Response · doi:10.1177/1559325820917829 · Cited by 17
Chemotherapy at the End of Life
Urvay, S., Civelek, B., Özaslan, E., & Sürel, A. A. (2020) · Journal of Palliative Care · doi:10.1177/0825859720946505 · Cited by 17
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS -mutated metastatic colorectal cancer: the REVOLUTION study protocol
Avallone, A., Piccirillo, M. C., Gennaro, E. D., Romano, C., Calabrese, F., Roca, M. S., Tatangelo, F., Granata, V., Cassata, A., Cavalcanti, E., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920929589 · Cited by 17
Effects of multidisciplinary team on the outcomes of colorectal cancer patients with liver metastases
Li, X., Chen, Q., Bi, X., Zhao, J., Li, Z., Zhou, J., Huang, Z. K., Zhang, Y., Mao, R., Zhao, H., et al. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-193 · Cited by 17
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
Rossini, D., Lonardi, S., Antoniotti, C., Santini, D., Tomasello, G., Ermacora, P., Germani, M. M., Bergamo, F., Ricci, V., Caponnetto, S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01089-9 · Cited by 18
Self-citation

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks